Denosumab in osteoporosis and oncology (Q37557994)

21 August 2017

1 reference

title

Denosumab in osteoporosis and oncology (English)

1 reference

21 August 2017

0 references

Jill S Burkiewicz

1

1 reference

21 August 2017

Sarah L Scarpace

series ordinal

2

1 reference

21 August 2017

Susan P Bruce

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

21 July 2009

1 reference

Annals of Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

43

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1445-1455

1 reference

Loss of treatment benefit due to low compliance with bisphosphonate therapy

21 August 2017

cites work

1 reference

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

21 January 2018

1 reference

RANKL signaling in bone physiology and cancer

21 January 2018

1 reference

RANK ligand inhibition with denosumab for the management of osteoporosis

21 January 2018

1 reference

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

Mechanisms of bone metastasis

21 January 2018

1 reference

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls

21 January 2018

1 reference

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

Denosumab: anti-RANKL antibody

21 January 2018

1 reference

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

21 January 2018

1 reference

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates

21 January 2018

1 reference

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M102

1 reference

21 August 2017

1 reference